36 results on '"Hyman, D.M."'
Search Results
2. Characterization of on-target adverse events caused by TRK inhibitor therapy
3. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
4. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
5. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
6. Oncologist use and perception of large panel next-generation tumor sequencing
7. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
8. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
9. Building bridges between drug development and cancer science: a tribute to José Baselga's legacy
10. P86.03 A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations
11. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial
12. Immune and genomic profiling of small cell carcinomas of the ovary hypercalcemic type
13. 553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J
14. B04 Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer
15. Étude de phase II « basket » évaluant l’efficacité de l’anticorps monoclonal bispécifique anti-HER2/HER3 MCLA-128 chez les patients atteints de tumeurs solides avancées présentant un réarrangement NRG1
16. Foreword
17. A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
18. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
19. Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
20. Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
21. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
22. Clinical outcomes of patients with pole mutated endometrioid endometrial cancer
23. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial
24. Clinical outcomes of patients with POLE-mutated endometrioid endometrial cancer
25. Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
26. A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC)
27. 1196P - Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
28. 685TiP - A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
29. 485P - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
30. 445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
31. 444PD - Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
32. 30P - Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
33. 970P - A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC)
34. Methodology for determining occluded gas contents in domal rock salt
35. Methane content of Gulf Coast domal rock salt
36. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT 'basket' trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.